Tagged with Biogen

Saudi Arabia Biogen’s manager for the Middle East, Africa, Russia & CIS, Turkey (MART), Ajai Sulekh, discusses the company’s five-pillar strategy to expand its footprint in the region, the importance of its newly established technical & scientific office in Saudi Arabia, and why the Kingdom is part of “almost every discussion” about…

Denmark Long established as a premier early launch country for innovative medicines within Europe, the Danish market access system has become more complicated of late as the Danish Medicines Council – the body charged with providing guidance about new medicines for use in the Danish hospital sector – adjusts to the…

Denmark Tashia Lentz of Biogen outlines what she sees as an increasingly tough market access environment for new treatments in Denmark and calls for greater stakeholder openness to innovative pricing schemes. Lentz also makes a comparison between the life sciences ecosystems in Sweden, where she spent three years heading up Astellas’…

USA In his latest PharmaBoardroom piece, John Singer looks at Biogen’s marketing campaign for its new Alzheimer’s drug, extending and linking the controversy to the grander strategic themes reshaping the ‘drug market’ as a whole, including the impact of the internet on cognitive change, the unmet need for a different premise for…

China The latest news from the Chinese pharmaceutical industry, including recent deals between domestic pharma giant Simcere and German biotech Vivoryon in Alzheimer’s; Innovent’s tie-up with Ascentage; Biogen’s USD 125 million midstage MS drug pact with InnoCare; and Everest Medicines’ partnership with social media giant Tencent.   Sinopharm Tops Ranking of…

Switzerland Mental health is a global crisis. 25 percent of the world’s population struggle with mental illness; and mental, neurological, and substance use disorders account for 11 percent of the total global disease burden according to data from the Healthy Brains Global Initiative (HBGI). Global mental healthcare costs are expected to…

USA With the US FDA’s controversial recent decision to approve Biogen and Eisai’s aducanumab – the first approval for a new Alzheimer’s disease (AD) drug since 2003 – PharmaBoardroom has raided its archives to bring key industry stakeholders’ takes on the significance of this decision and what it might mean for…

USA Taking the example of music’s effect on Alzheimer’s disease patients, John G Singer makes the case for a more holistic approach to healthcare; focusing less on the transformative potential of individual drugs and more on value as a stream of benefits delivered through a living system.   Singer/songwriter Glen Campbell,…

Switzerland Biogen Switzerland’s Dr med Katharina Gasser outlines how her affiliate navigated the COVID-19 pandemic from an organisational and communication perspective, the increasing importance being given to mental health by the Swiss government, and the reimbursement and market challenges facing Biogen in 2021 and beyond.   2020 saw a lot of…

Switzerland Antonella Santuccione Chadha*, Head of Stakeholder Engagement for Alzheimer’s disease at Biogen and co-founder and CEO of the Women’s Brain Project, dives into the non-profit organization’s role in rethinking the way we look at sex and gender as a gateway to precision medicine. She explains how artificial intelligence (AI) is…

Switzerland This article forms part of Healthcare & Life Sciences Review: Switzerland February 2021, a comprehensive up-to-date country report on the Swiss pharma market, featuring data snapshots, feature articles, exclusive interviews and more. Click here to download.   Long heralded as an innovation powerhouse able to hold its own against the…

Switzerland A trained physician with several years of practice under her belt, Katharina Gasser then moved into clinical research as an investigator before joining the pharma industry in 2005. Now head of Biogen’s Swiss affiliate and chair of the executive committee of industry association Interpharma, Gasser cites her diverse background as…